

<https://doi.org/10.1038/s41531-025-01116-7>

Increased frontal [123 I]FP-CIT binding in Parkinson's disease patients with self-reported REM sleep behavior disorder

Check for updates

Elina Jaakkola^{1,2,3,9} ✉, Jani Ijas^{1,2,9}, Juho Joutsa^{1,2,4}, Tero Vahlberg⁵, Elina Myller^{1,2}, Mikael Eklund^{1,2}, Simo Nuutila¹, Kirsi Murtomäki⁶, Tuomas Mertsalmi⁶, Reeta Levo⁶, Tommi Noponen⁷, Toni Ihalainen⁸, Filip Scheperjans⁶ & Valtteri Kaasinen^{1,2} ✉

Rapid eye movement (REM) sleep behavior disorder (RBD) is a frequent non-motor symptom of Parkinson's disease (PD) and a potential early marker of synucleinopathy-related neurodegeneration. While striatal dopaminergic dysfunction in PD-RBD has been extensively studied, the role of extrastriatal monoaminergic alterations -particularly those involving serotonin - remains poorly understood. In this study, 155 PD patients underwent [123 I]FP-CIT SPECT imaging to assess striatal and extrastriatal tracer binding, reflecting dopaminergic and broader monoaminergic function, respectively. Probable RBD was identified using a validated single-question screening tool with high sensitivity and specificity. Patients with probable RBD (RBD +, $n = 44$) were compared to those without (RBD -, $n = 111$) using voxel-wise and region-of-interest analyses, controlling for age, sex, disease duration, motor and non-motor symptom severity, and cognitive function. No significant differences were observed in striatal dopamine transporter binding. However, RBD+ patients showed significantly higher extrastriatal binding in the prefrontal cortex (pFWE < 0.05), suggesting a potential role for altered extrastriatal monoaminergic neurotransmission, possibly involving serotonergic pathways, in PD-RBD pathophysiology. These findings should be interpreted with caution due to the non-selective binding profile of the radiotracer.

Rapid eye movement (REM) sleep behavior disorder (RBD) is a condition characterized by the enactment of dreams and complex motor behaviors, such as kicking, laughing, or crying during REM sleep¹. Unlike in normal REM sleep, individuals with RBD have an absence of the typical muscle atonia. This disorder is closely associated with synucleinopathic neurodegeneration observed in Parkinson's disease (PD), dementia with Lewy bodies, multiple system atrophy and pure autonomic failure¹. RBD can emerge as an early warning sign for these conditions, manifesting many years before the onset of motor or cognitive decline². As such, RBD not only serves as a specific marker of synucleinopathies but also appears to demonstrate predictive power².

In the context of brain dopaminergic function, idiopathic RBD (iRBD) patients have been found to have reduced striatal dopamine transporter

(DAT) uptake when compared to healthy controls, suggesting the role of iRBD as a premotor symptom of synucleinopathy leading to dopaminergic degeneration^{3,4}. However, investigations into DAT activity among RBD-positive and RBD-negative PD patients have shown conflicting results. Some studies have suggested decreased DAT binding in the striatum in PD-RBD compared to PD patients without RBD⁵⁻⁷, while other studies have shown no differences in striatal DAT between PD patients with or without RBD^{8,9}, with the possibility of later decline in DAT binding¹⁰.

Beyond dopamine, several other neurotransmitters systems, including cholinergic, noradrenergic and serotonergic systems, are involved in PD pathophysiology¹¹. Among these, emerging evidence suggests that serotonergic function may have particular relevance to RBD in PD. The

¹Clinical Neurosciences, University of Turku, Turku, Finland. ²Neurocenter, Turku University Hospital, Turku, Finland. ³Department of Psychiatry, University of Helsinki and Helsinki University Hospital, Helsinki, Finland. ⁴Turku Brain and Mind Center, Turku PET Center, University of Turku, Turku, Finland. ⁵Department of Biostatistics, University of Turku and Turku University Hospital, Turku, Finland. ⁶Department of Neurology, Helsinki University Hospital and Department of Clinical Neurosciences (Neurology), University of Helsinki, Helsinki, Finland. ⁷Department of Clinical Physiology, Nuclear Medicine, Turku PET Centre and Medical Physics, Turku University Hospital and Wellbeing services county of Southwest Finland, Turku, Finland. ⁸Department of Clinical Physiology and Nuclear Medicine, Helsinki University Hospital and University of Helsinki, Helsinki, Finland. ⁹These authors contributed equally: Elina Jaakkola, Jani Ijas. ✉e-mail: elanja@utu.fi; valtteri.kaasinen@tyks.fi

serotonergic system has a modulatory effect of sleep-wake cycle¹², acute RBD can be induced by selective serotonin reuptake inhibitors (SSRIs) and selective serotonin and noradrenalin reuptake inhibitors (SNRIs)¹³, and 5-hydroxytryptophan (5-HTP), a precursor of serotonin and melatonin, may ameliorate RBD symptoms in PD¹⁴, further implicating the serotonergic system in the underlying mechanism of RBD.

A limited number of neuroimaging studies with relatively small sample sizes have specifically examined serotonin function in PD in relation to RBD. A positron emission tomography (PET) study using the serotonin transporter (SERT) ligand [¹¹C]DASB, focusing on the raphe nucleus and striatum, reported no differences in SERT binding between RBD-positive and RBD-negative PD patients (*n* = 11 vs 24)¹⁵. Another study, using [¹²³I]FP-CIT SPECT to examine the brainstem and thalamus, similarly found no differences in SERT function between iRBD patients and healthy controls (*n* = 20 vs 23)¹⁶. However, a separate PET study with [¹¹C]DASB demonstrated reduced SERT activity in the striatum, raphe nuclei and hypothalamus in PD patients with sleep disturbances compared to those without sleep dysfunction (*n* = 14 vs 14), although this study did not specifically compare RBD+ and RBD- patients¹⁷. The previous studies predominantly restricted analyses to subcortical brain regions.

Given the limited number of neuroimaging studies exploring monoaminergic function in PD with RBD, particularly in cortical regions, and the potential importance of serotonin in the treatment and pathophysiology of RBD, we conducted a larger-scale investigation compared to previous studies. This study utilized [¹²³I]FP-CIT SPECT, a monoaminergic tracer commonly used to assess DAT binding in the striatum, while investigating its potential to reflect broader monoaminergic activity and possible SERT binding¹⁸ in cortical regions using voxel-wise image analysis. Given the modest affinity of [¹²³I]FP-CIT for the SERT and its non-selective binding profile outside the striatum, the findings from this study should be interpreted as exploratory with respect to underlying neurotransmitter specificity.

Results

Demographics

Of the 155 patients included, 44 (28.4%) were classified as having self-reported probable RBD (RBD +), while 111 (71.6%) were without RBD (RBD-). RBD+ patients had longer motor symptom duration compared to RBD- patients (Table 1). No significant differences were observed between the groups in terms of age, sex, Movement Disorder Society - Unified Parkinson's Disease Rating Scale (MDS-UPDRS) motor scores, total Non-Motor Symptoms Scale (NMSS) scores, Beck Depression Inventory (BDI) scores, use of dopaminergic or antidepressant medications, levodopa equivalent daily dose (LEDD), or use of alcohol, coffee, or nicotine. Cognitive performance, as measured by the Mini-Mental State Examination (MMSE), was significantly lower in RBD+ patients compared to RBD- patients (Table 1).

Region of interest analyses

In the region of interest (ROI) analyses, left caudate Specific binding ratios (SBRs) were lower at a trend level in RBD+ patients compared to RBD- patients (Table 1). However, no significant differences in striatal SBRs were observed between the groups after controlling for the effects of covariates (Table 2). The results remained unchanged when motor symptom duration was included as an additional covariate in the model. To assess the statistical power of the ROI-based group comparison, we conducted a post hoc power analysis. Based on the observed difference in frontal SBR (mean 1.17 [SD 0.15] in RBD+ vs. 1.08 [SD 0.12] in RBD -), the estimated effect size (Cohen's *d*) was 0.70. Given the group sizes (*n* = 44 vs. 111), the calculated power was 97.3% at $\alpha = 0.05$ (two-sided), indicating that the analysis was well powered to detect the observed effect.

Voxel-wise analyses

Whole-brain voxel-wise analyses revealed significantly increased [¹²³I]FP-CIT binding in the frontal cortex of RBD+ patients compared to RBD-

Table 1 | Demographic and clinical characteristics of the studied sample

		RBD + (<i>n</i> = 44)	RBD - (<i>n</i> = 111)	<i>p</i> value
Demographics	Age (years)	67.5 [15]	66.0 [17]	0.19 ^a
	Sex (m/f)	26/18	48/63	0.075 ^b
Motor symptoms	MDS-UPDRS motor score	31.0 [13]	34.0 [21]	1.0 ^a
	Motor symptom duration (mo)	24.0 [43]	15 [19]	0.014 ^a
	Hoehn and Yahr scale	2.0 [0]	2.0 [1]	0.15 ^a
Non-motor symptoms	NMSS total score	46.0 [54]	36.0 [46]	0.055 ^a
	Cardiovascular incl. falls	0.0 [3]	0.0 [3]	0.97 ^a
	Sleep/fatigue	10.5 [13]	6.0 [15]	0.15 ^a
	Mood/cognition	3.0 [11]	2.0 [12]	0.77 ^a
	Perceptual problems	0.0 [0]	0.0 [0]	0.72 ^a
	Attention/Memory	3.0 [7]	1.0 [4]	0.060 ^a
	Gastrointestinal tract	1.0 [7]	0.0 [4]	0.26 ^a
	Urinary	8.0 [20]	5.0 [11]	0.030 ^a
	Sexual function	0.0 [6]	0.0 [4]	0.29 ^a
	Miscellaneous	8.0 [13]	4.0 [12]	0.29 ^a
	BDI score	7.0 [7]	6.0 [9]	0.16 ^a
	MMSE score	27.0 [3]	28.0 [3]	0.003 ^a
Medications	Dopaminergic drug users	17 (38.6)	30 (27.0)	0.16 ^b
	Levodopa users	11 (25.0)	18 (16.2)	0.21 ^b
	LEDD	0.0 [200]	0.0 [75]	0.23 ^a
	Clonazepam users	3 (6.8)	0 (0.0)	0.022 ^c
	Melatonin users	3 (6.8)	1 (0.9)	0.069 ^c
	Antidepressant users	4 (9.1)	16 (14.4)	0.37 ^b
Psychoactive substances	Nicotine users	7 (15.9)	8 (7.2)	0.13 ^c
	Alcohol (drinks/week)	1.0 [4]	1.0 [4]	0.84 ^a
	Coffee (cups/day)	3.0 [3]	3.0 [3]	0.73 ^a
Striatal DAT binding	Right caudate	1.92 [0.70]	2.11 [0.80]	0.063 ^a
	Left caudate	1.81 [0.92]	2.14 [0.80]	0.012 ^a
	Right anterior putamen	1.33 [0.73]	1.67 [0.92]	0.048 ^a
	Left anterior putamen	1.31 [0.79]	1.61 [0.84]	0.058 ^a
	Right posterior putamen	0.88 [0.52]	0.97 [0.61]	0.49 ^a
	Left posterior putamen	0.89 [0.60]	0.90 [0.59]	0.63 ^a

Values are median [IQR] or *n* (%).

RBD REM sleep behavior disorder, *m* male, *f* female, *mo* months, NMSS Non-Motor Symptoms Scale, BDI Beck depression inventory, MMSE Mini-Mental State Examination, LEDD levodopa equivalent daily dose, DAT dopamine transporter.

^aMann-Whitney U-test.

^bPearson's Chi-squared test.

^cFisher's exact test.

Table 2 | ANCOVA analysis with DAT binding as dependent variable

Dependent variable	Independent variable	RBD+ Adjusted ^a mean (SE)	RBD- Adjusted ^a mean (SE)	Adjusted ^a mean difference for RBD (95% CI)	P value
Right caudate	RBD	2.01 (0.10)	2.15 (0.06)	-0.14 (-0.37 to 0.09)	0.23
Left caudate	RBD	2.05 (0.10)	2.24 (0.06)	-0.19 (-0.42 to 0.03)	0.095
Right anterior putamen	RBD	1.51 (0.10)	1.73 (0.06)	-0.21 (-0.45 to 0.02)	0.075
Left anterior putamen	RBD	1.50 (0.09)	1.65 (0.05)	-0.15 (-0.36 to 0.06)	0.15
Right posterior putamen	RBD	1.03 (0.09)	1.13 (0.06)	-0.10 (-0.32 to 0.13)	0.40
Left posterior putamen	RBD	0.99 (0.07)	0.96 (0.04)	0.03 (-0.14 to 0.20)	0.70

DAT Dopamine transporter, RBD REM sleep behavior disorder, MDS-UPDRS Movement Disorder Society's Unified Parkinson's Disease Rating Scale, MMSE Mini-Mental State Examination, NMSS Non-Motor Symptoms Scale.

^aAge, sex, MDS-UPDRS motor score, MMSE score and NMSS total score were used as covariates in ANCOVA.




Fig. 1 | Increased [¹²³I]FP-CIT binding in patients with probable REM sleep behavior disorder (RBD+) compared to those without RBD (RBD-). The image displays regions showing significantly higher binding in RBD+ patients, with results

thresholded at cluster-level FWE-corrected $P < 0.05$ (Cluster 1, size 5303 voxels; Cluster 2, size 5843 voxels; FWE-corrected $P < 0.001$). No regions showed significantly lower binding in RBD+ patients relative to RBD- patients.

patients, after adjusting for age, sex and MDS-UPDRS Part III motor scores (FWE-corrected $P < 0.05$, Fig. 1). This finding remained significant when MMSE and NMSS scores were included as additional covariates (FWE-corrected $P = 0.008$; cluster size = 2349 voxels). Similarly, the result persisted when patients using antidepressant medications ($n = 20$) were excluded from the analysis (Cluster 1: 5924 voxels, FWE-corrected $P < 0.001$; Cluster 2: 2922 voxels, FWE-corrected $P = 0.005$). Exploratory correlation analysis between mean frontal cluster SBR and MMSE scores showed no significant association across the whole sample ($r = -0.09$, $p = 0.28$). The mean SBR within the identified frontal cluster was 9.2% higher in RBD+ patients (mean [SD] 1.17 [0.15]) compared to RBD- patients (1.08 [0.12]). No significant group differences in striatal [¹²³I]FP-CIT binding were observed in the voxel-wise analysis.

Discussion

The findings of this study demonstrate an association between self-reported RBD and increased monoaminergic binding in frontal brain regions, suggesting that alterations in frontal extrastriatal monoaminergic neurotransmission, possibly involving serotonergic pathways, may contribute to the pathophysiology of PD-related RBD. The absence of significant differences in striatal DAT binding between RBD+ and RBD- patients suggests that, at least beyond the initial motor symptom onset, dopaminergic dysfunction may not be the primary contributor to RBD in PD. These results support the growing view that non-dopaminergic systems, including cortical monoaminergic pathways, may play a role in the development of RBD.

Previous research on dopaminergic dysfunction in PD patients with RBD has yielded inconsistent findings. While some studies have reported reduced striatal DAT binding in RBD+ patients, these results have often

been associated with greater motor impairment in the RBD+ group, raising the possibility that the observed reductions in DAT binding may reflect disease severity rather than a specific link to RBD⁵. Moreover, some of these differences have not remained significant after adjusting for confounding factors such as age, sex, and disease duration, or after correction for multiple comparisons^{6,19}. Data from the Parkinson's Progression Markers Initiative (PPMI) have also been mixed, with some studies reporting mildly decreased striatal DAT binding in RBD+ patients at baseline^{20,21}, while others have found no group differences – consistent with our current findings^{9,10}. These inconsistencies demonstrate the complexity of interpreting dopaminergic alterations in PD-RBD and suggest that changes in dopaminergic pathways may be subtle and dependent on study design, sample characteristics, and methodological approaches.

Although no differences in striatal DAT binding were observed between RBD+ and RBD- patients, a clear increase in tracer binding was observed in a region which encompassed several frontal cortical areas. Although FP-CIT is not a specific SERT tracer, we interpret this extrastriatal finding as likely reflecting general monoaminergic activity in the frontal region. While SERT may contribute to this signal, the interpretation should remain cautious due to the limited specificity of [¹²³I]FP-CIT. Experimental studies have demonstrated that the tracer's selectivity favors DAT, with reported Ki values of approximately 3.5 nM for DAT and 9.7 nM for SERT in human tissue²². While this limits its utility for SERT-specific imaging, prior SPECT studies have nonetheless suggested that [¹²³I]FP-CIT can detect serotonergic alterations in brainstem and thalamic regions in vivo, although signal reliability in cortical areas remains lower^{23,24}. Experimental blocking studies with SSRIs such as paroxetine have further shown that FP-CIT binding is partially attributable to SERT, reinforcing its potential utility

in detecting monoaminergic changes beyond the striatum²⁵. While the absolute extrastriatal SBR values were modest, the observed group-level difference exceeded the typical test-retest variability reported for striatal FP-CIT binding, suggesting a reproducible effect. Moreover, similar cortical binding levels have been reported in autopsy-confirmed PD cohorts using FP-CIT SPECT²⁶, supporting the detectability of cortical signal *in vivo*.

The biological relevance of this increased frontal binding remains unclear and may reflect transporter regulation, compensatory mechanisms, or unrelated monoaminergic changes. Given that several prior studies have reported reduced serotonergic innervation in RBD, one possibility is that increased SERT availability in our study reflects a compensatory upregulation of transporter expression in response to early neurotransmitter depletion. In addition to compensatory SERT upregulation in response to reduced synaptic serotonin, alternative explanations merit consideration. For example, [¹²³I]FP-CIT demonstrates modest affinity not only for SERT but also for the noradrenergic transporter, suggesting that noradrenergic binding may partially contribute to the extrastriatal signal²⁷. Moreover, cortical FP-CIT uptake may be influenced indirectly by changes in GABAergic or glutamatergic circuitry regulating transporter density or function, a pathway that remains largely unexplored. Without direct synaptic serotonin measures or selective PET imaging, these competing interpretations remain plausible but unconfirmed. The finding may also reflect subtype-specific neurodegeneration patterns. According to the body-first vs. brain-first hypothesis of PD, RBD is typically associated with the body-first subtype, which exhibits early peripheral pathology and more widespread cortical involvement²⁸. The observed frontal monoaminergic differences may thus reflect divergent neurodegeneration trajectories rather than a direct mechanistic link to RBD symptoms. However, the SERT interpretation is partially supported by earlier studies suggesting that extrastriatal [¹²³I]FP-CIT reflects SERT density, as FP-CIT has moderate affinity to SERT^{18,22,29}. In PD, SERT levels are generally reduced in the raphe nuclei, striatum, thalamus, and hypothalamus, with more pronounced motor symptoms correlating with greater reductions in SERT activity³⁰. In contrast, PD patients with depression have been reported to show increased SERT activity in the limbic system and raphe nuclei³⁰. Nevertheless, studies specifically examining serotonergic function in PD patients with RBD remain scarce. Kotagal et al. investigated SERT function in PD-RBD using PET with the SERT ligand [¹¹C]DASB and found no significant differences in brainstem or striatal SERT binding between PD patients with and without RBD. In contrast, their study showed widespread cholinergic denervation in multiple brain regions among PD-RBD patients¹⁵. Findings from studies of iRBD without PD are similarly inconsistent. A study using [¹²³I]FP-CIT SPECT to assess the relationship between SERT binding and iRBD reported no differences between iRBD patients and controls. This study focused only on brainstem and thalamic regions, excluding cortical areas, which may have contributed to the negative findings¹⁶. In contrast, a PET study using the SERT ligand [¹¹C]DASB in iRBD patients found reduced SERT densities in the neocortex, insula and putamen compared to control subjects³¹. However, the control group in this study was younger than the iRBD group, potentially confounding the results. Considering the findings in iRBD, it is important to note that the present study examined PD patients rather than comparing iRBD patients to healthy controls. This distinction is crucial when interpreting differences across studies, as the underlying neurodegenerative processes in PD could significantly change the role of SERT in the pathophysiology of RBD.

Increased frontal monoaminergic activity, potentially involving serotonergic mechanisms, could be associated with multiple features of RBD and sleep regulation, as serotonin plays an important role in maintaining wakefulness and preventing REM sleep³². Serotonergic dysfunction has been implicated in RBD pathophysiology, as evidenced by the observation that antidepressants, particularly SSRIs and SNRIs, may cause REM sleep without atonia (RSWA) or trigger RBD. This suggests that elevated serotonin activity could contribute to the disruption of normal REM sleep mechanisms. However, in the absence of polysomnographic data or symptom-specific correlations in the current study, such mechanisms remain speculative.

Further studies should be carried out to investigate the structure of sleep and RBD characteristics in relation to frontal SERT changes.

There are certain limitations in the present study. First, RBD was identified using a single-question screening tool rather than polysomnography, which is the gold standard for RBD diagnosis. However, the screening tool used in this study has been validated in a multicenter setting, demonstrating a sensitivity of 93.8% and a specificity of 87.2%³³. To account for this limitation, we classified cases as *self-reported* rather than *confirmed* RBD, and further studies incorporating full polysomnography are needed to validate these findings. Second, the patient cohort in this study may not fully represent broader PD population, as all participants underwent [¹²³I]FP-CIT SPECT imaging due to initial diagnostic uncertainty. This selection criterion could introduce a bias toward atypical and diagnostically challenging cases. Third, although there were no significant group differences in the use of dopaminergic or serotonergic medications, and only three patients reported clonazepam use, the potential confounding effects of medications such as antidepressants or benzodiazepines on monoaminergic tracer binding and RBD symptom expression cannot be entirely excluded. Future studies with larger samples could stratify analyses by medication class or include pharmacodynamic modeling to further assess these effects. Fourth, while global cognitive function was adjusted for using MMSE scores, we did not have access to cognitive domain-specific subscores. This limits our ability to assess whether frontal monoaminergic binding is related to particular cognitive components (e.g., executive function), which may be relevant given the frontal localization of the signal. Fifth, while the voxel-wise imaging analyses were corrected for multiple comparisons using FWE correction, the ROI-based and clinical comparisons were not. These secondary analyses were considered exploratory, but this limitation should be acknowledged when interpreting subgroup differences and associations. Finally, some patients characterized as non-RBD at the time of assessment may develop RBD in over time, as RBD symptoms can emerge later in the disease course. Longitudinal follow-up studies are required to assess the potential conversion of non-RBD patients to RBD+ status and to better understand the progression of serotonergic changes in PD.

In conclusion, this study provides evidence of increased frontal [¹²³I]FP-CIT binding in PD patients with self-reported RBD, which may reflect altered extrastriatal monoaminergic neurotransmission. Although serotonergic mechanisms could contribute, the specificity of the tracer does not permit definitive conclusions. These findings raise the possibility that serotonergic changes may contribute to, or compensate for, sleep-related dysfunction. Future studies are needed to clarify the biological basis of increased frontal monoaminergic binding in PD-RBD. These should ideally incorporate longitudinal polysomnographic assessments, symptom severity correlations, and neuroimaging with selective SERT ligands such as [¹¹C]DASB. Such data would help distinguish whether the observed binding patterns reflect primary pathophysiological changes, compensatory neurotransmitter regulation, or downstream consequences of neurodegeneration. Future studies should also examine extrastriatal monoaminergic binding patterns in patients with iRBD to assess whether similar cortical changes precede the onset of PD. Comparative analyses across iRBD, PD-RBD, and non-RBD PD populations could help clarify the timing and progression of cortical monoaminergic alterations across disease stages.

Methods

Patients and study design

Between 2014 and 2019, patients undergoing [¹²³I]FP-CIT SPECT imaging due to clinically uncertain parkinsonism or tremor at Turku University Hospital or Helsinki University Hospital in Finland were recruited for this study (NMDAT study; ClinicalTrials.gov identifier: NCT02650843). The study cohort has been comprehensively described in previous reports^{34–37}. All participants underwent clinical examination 3–4 hours before imaging. These evaluations included a neurological clinical examination with a clinical interview, MDS-UPDRS part III³⁸, MMSE³⁹, BDI⁴⁰, and NMSS⁴¹. All investigators had completed the MDS-UPDRS Training Program and Exercise certification.

Final PD diagnoses were confirmed through chart review by two movement disorder specialists 3–8 years after imaging, taking into account clinical progression, phenotype, treatment response and imaging findings. Patients with an MMSE score <18 ($n = 1$) or incomplete imaging data ($n = 2$) were excluded from the study. Written informed consent was obtained from all participants in accordance with the Declaration of Helsinki, and the study was approved by the local ethics committee.

RBD assessment

The presence of self-reported RBD was assessed using the validated single-question screen for RBD (RBDQ1)³³. The screening question asks: “Have you ever been told, or suspected yourself, that you seem to ‘act out your dreams’ while asleep (for example, punching, flailing your arms in the air, making running movements, etc.)?” Participants provide a simple “yes” or “no” response. The RBDQ1 has been validated against polysomnogram in a multicenter, well-characterized clinical cohort, with a demonstrated sensitivity of 94% and specificity of 87% for detecting probable RBD³³.

Image acquisition and preprocessing

Patients received an intravenous injection of 185 MBq of [¹²³I]FP-CIT three hours prior to SPECT imaging. To minimize radiation exposure to the thyroid gland, patients were pretreated with either potassium perchlorate (250–300 mg) or potassium iodine (130 mg) 30–60 min before the radiotracer injection. The imaging was performed using eight different SPECT/CT devices, all calibrated prior to the study using a striatal phantom (Radiology Support Devices, Inc., Long Beach, CA, USA) to ensure comparability across systems. Calibration procedures followed the guidelines provided by Hermes Medical Solutions^{42,43}. SPECT data were reconstructed using the 3D OSEM algorithm with corrections for attenuation, collimator response and scatter applied (HybridRecon Neurology, version 1.3, Hermes Medical Solutions AB, Stockholm, Sweden). The acquisition and reconstruction protocols adhered to the European Association of Nuclear Medicine (EANM) recommendations across all devices⁴⁴.

Region of interest analyses

Reconstructed SPECT images were analyzed using the BRASS semi-automated analysis software (version 2.6, Hermes Medical Solutions, Stockholm, Sweden), incorporating scanner-specific corrections derived from prior calibrations. SBRs were calculated for six volumes of interest (VOIs): left and right caudate, anterior putamen and posterior putamen. The occipital cortex served as the reference area, and the SBRs were computed using the formula⁴⁴:

$$\text{SBR} = \left(\text{VOI}_{\text{caudate or putamen}} - \text{VOI}_{\text{occipital}} \right) / \text{VOI}_{\text{occipital}}$$

Voxelwise analyses

Voxelwise analyses were conducted using general linear model implemented in Statistical Parametric Mapping (SPM12, <https://www.fil.ion.ucl.ac.uk/spm/software/spm12/>) software to investigate associations between RBD status and both striatal and extrastriatal [¹²³I]FP-CIT binding. The SBR images realigned in the BRASS analysis were normalized to Montreal Neurological Institute (MNI) space using an in-house MNI space [¹²³I]FP-CIT template, as described previously⁴⁵. The search volume in the voxelwise analyses was restricted to brain regions showing specific binding. Age, sex and UPDRS-III score were used as nuisance covariates. To ensure that the results are not driven by other non-motor symptoms or cognitive impairment, the analyses were confirmed by using MMSE score and NMSS score as additional covariates to the model. Cluster-level family-wise error (FWE) corrected P -values less than 0.05 were considered significant.

Statistical analyses

Statistical analyses were performed using IBM SPSS Statistics (version 29, SPSS Inc., Chicago, Illinois, USA). The normality of the variables was

assessed a combination of visual inspection of histograms and the Shapiro-Wilk test. Differences between patients with and without probable RBD were analyzed using the Mann–Whitney U-test for continuous variables and either the Chi-square test or Fisher’s exact test for categorical variables, as appropriate. Analysis of covariance (ANCOVA) was used to control the effects of covariate variables in SBRs. Like in voxelwise analyses, age, sex, MDS-UPDRS motor score, MMSE score and NMSS total score were used as covariates. Normality of residuals in ANCOVA models were checked and skewed residuals were met for three SBRs (right anterior putamen, left and right posterior putamen). To obtain normality, ANCOVA models were done using log transformed SBRs. Results remained unchanged and, to allow easier interpretation, results for untransformed SBRs are shown. Additional analyses were performed adding motor symptom duration to the model as well. Voxel-wise analyses were corrected for multiple comparisons using cluster-level family-wise error (FWE) correction at $p < 0.05$. Other comparisons, including clinical group differences, were conducted to characterize the sample and inform covariate selection, and were not corrected for multiple comparisons as they were not considered primary inferential outcomes.

Data availability

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Received: 9 April 2025; Accepted: 7 August 2025;

Published online: 14 August 2025

References

- Boeve, B. F. REM sleep behavior disorder: updated review of the core features, the REM sleep behavior disorder-neurodegenerative disease association, evolving concepts, controversies, and future directions. *Ann. N. Y. Acad. Sci.* **1184**, 15–54 (2010).
- Mahlknecht, P., Seppi, K. & Poewe, W. The concept of prodromal Parkinson’s disease. *J. Parkinsons Dis.* **5**, 681–697 (2015).
- Iranzo, A. et al. Serial dopamine transporter imaging of nigrostriatal function in patients with idiopathic rapid-eye-movement sleep behaviour disorder: a prospective study. *Lancet Neurol.* **10**, 797–805 (2011).
- Eisensehr, I. et al. Reduced striatal dopamine transporters in idiopathic rapid eye movement sleep behaviour disorder. *Comparison Parkinson’s Dis. Controls Brain* **123**, 1155–1160 (2000).
- Arnaldi, D. et al. Nigro-caudate dopaminergic deafferentation: a marker of REM sleep behavior disorder?. *Neurobiol. Aging* **36**, 3300–3305 (2015).
- Chung, S. J., Lee, Y., Lee, J. J., Lee, P. H. & Sohn, Y. H. Rapid eye movement sleep behaviour disorder and striatal dopamine depletion in patients with Parkinson’s disease. *Eur. J. Neurol.* **24**, 1314–1319 (2017).
- Cicero, C. E. et al. Exploring the relation between REM sleep behavior disorder onset and striatal dopaminergic dysfunction in Parkinson’s Disease. *J. Neurol.* **272**, 75 (2024).
- Valli, M. et al. VMAT2 availability in Parkinson’s disease with probable REM sleep behaviour disorder. *Mol. Brain* **14**, 165 (2021).
- Pagano, G. et al. REM behavior disorder predicts motor progression and cognitive decline in Parkinson disease. *Neurology* **91**, e894–e905 (2018).
- Kim, Y. E., Kim, Y. J., Hwang, H. S. & Ma, H. I. REM sleep behavior disorder in early Parkinson’s disease predicts the rapid dopaminergic denervation. *Parkinsonism Relat. Disord.* **80**, 120–126 (2020).
- Brichta, L., Greengard, P. & Flajolet, M. Advances in the pharmacological treatment of Parkinson’s disease: targeting neurotransmitter systems. *Trends Neurosci.* **36**, 543–554 (2013).
- Ursin, R. Serotonin and sleep. *Sleep. Med. Rev.* **6**, 55–69 (2002).
- Temam, P. T., Tippmann-Peikert, M., Silber, M. H., Slocumb, N. L. & Auger, R. R. Idiopathic rapid-eye-movement sleep disorder:

- associations with antidepressants, psychiatric diagnoses, and other factors, in relation to age of onset. *Sleep Med.* **10**, 60–65 (2009).
14. Meloni, M. et al. Preliminary finding of a randomized, double-blind, placebo-controlled, crossover study to evaluate the safety and efficacy of 5-hydroxytryptophan on REM sleep behavior disorder in Parkinson's disease. *Sleep Breath.* **26**, 1023–1031 (2022).
 15. Kotagal, V. et al. Symptoms of rapid eye movement sleep behavior disorder are associated with cholinergic denervation in Parkinson disease. *Ann. Neurol.* **71**, 560–568 (2012).
 16. Arnaldi, D. et al. The role of the serotonergic system in REM sleep behavior disorder. *Sleep* **38**, 1505–1509 (2015).
 17. Wilson, H., Giordano, B., Turkheimer, F. E., Chaudhuri, K. R. & Politis, M. Serotonergic dysregulation is linked to sleep problems in Parkinson's disease. *Neuroimage Clin.* **18**, 630–637 (2018).
 18. Koopman, K. E., la Fleur, S. E., Fliers, E., Serlie, M. J. & Booij, J. Assessing the optimal time point for the measurement of extrastriatal serotonin transporter binding with 123I-FP-CIT SPECT in healthy, male subjects. *J. Nucl. Med.* **53**, 1087–1090 (2012).
 19. Kwak, I. H. et al. Striatal subregion analysis associated with rem sleep behavior disorder in Parkinson's Disease. *J. Integr. Neurosci.* **22**, 18 (2023).
 20. Cao, R., Chen, X., Xie, C., Hu, P. & Wang, K. Serial dopamine transporter imaging of nigrostriatal function in Parkinson's disease with probable REM sleep behavior disorder. *Front. Neurosci.* **14**, 349 (2020).
 21. Liu, R., Umbach, D. M., Tröster, A. I., Huang, X. & Chen, H. Non-motor symptoms and striatal dopamine transporter binding in early Parkinson's disease. *Parkinsonism Relat. Disord.* **72**, 23–30 (2020).
 22. Abi-Dargham, A. et al. SPECT imaging of dopamine transporters in human brain with iodine-123-fluoroalkyl analogs of beta-CIT. *J. Nucl. Med.* **37**, 1129–1133 (1996).
 23. Nicasastro, N., Fleury, V., Broc, N., Burkhard, P. R. & Garibotto, V. Extrastriatal 123I-FP-CIT SPECT impairment in degenerative Parkinsonisms. *Parkinsonism Relat. Disord.* **78**, 38–43 (2020).
 24. van der Zande, J. J. et al. Serotonergic deficits in dementia with Lewy bodies with concomitant Alzheimer's disease pathology: An 123I-FP-CIT SPECT study. *Neuroimage Clin.* **25**, 102062 (2020).
 25. Booij, J. et al. Quantification of striatal dopamine transporters with 123I-FP-CIT SPECT is influenced by the selective serotonin reuptake inhibitor paroxetine: a double-blind, placebo-controlled, crossover study in healthy control subjects. *J. Nucl. Med.* **48**, 359–366 (2007).
 26. Pilotto, A. et al. Extrastriatal dopaminergic and serotonergic pathways in Parkinson's disease and in dementia with Lewy bodies: a. *Eur. J. Nucl. Med. Mol. Imaging* **46**, 1642–1651 (2019).
 27. Günther, I. et al. [125I] beta-CIT-FE and [125I] beta-CIT-FP are superior to [125I] beta-CIT for dopamine transporter visualization: autoradiographic evaluation in the human brain. *Nucl. Med. Biol.* **24**, 629–634 (1997).
 28. Borghammer, P. & Van Den Berge, N. Brain-first versus gut-first Parkinson's disease: a hypothesis. *J. Parkinsons Dis.* **9**, S281–S295 (2019).
 29. Ziebell, M. et al. Serotonin transporters in dopamine transporter imaging: a head-to-head comparison of dopamine transporter SPECT radioligands 123I-FP-CIT and 123I-PE2I. *J. Nucl. Med.* **51**, 1885–1891 (2010).
 30. Pagano, G., Niccolini, F., Fusar-Poli, P. & Politis, M. Serotonin transporter in Parkinson's disease: a meta-analysis of positron emission tomography studies. *Ann. Neurol.* **81**, 171–180 (2017).
 31. Garwood, M., Vijayakumar, P., Bohnen, N. I., Koeppe, R. A. & Kotagal, V. Serotonin transporter density in isolated rapid eye movement sleep behavioral disorder. *Front. Sleep* **2**. <https://doi.org/10.3389/frsle.2023.1298854> (2024).
 32. Monti, J. M. Serotonin control of sleep-wake behavior. *Sleep Med. Rev.* **15**, 269–281 (2011).
 33. Postuma, R. B. et al. A single-question screen for rapid eye movement sleep behavior disorder: a multicenter validation study. *Mov. Disord.* **27**, 913–916 (2012).
 34. Jaakkola, E. et al. Burden of non-motor symptoms in unclear Parkinsonism and tremor: a study with. *J. Neurol. Sci.* **404**, 124–127 (2019).
 35. Murtoimäki, K. et al. Dopamine transporter binding in the brain is linked to irritable bowel syndrome in Parkinson's disease. *Brain Behav.* **13**, e3097 (2023).
 36. Eklund, M. et al. Diagnostic value of micrographia in Parkinson's disease: a study with. *J. Neural Transm.* **129**, 895–904 (2022).
 37. Murtoimäki, K. et al. Gastrointestinal symptoms and dopamine transporter asymmetry in early Parkinson's disease. *Mov. Disord.* **37**, 1284–1289 (2022).
 38. Goetz, C. G. et al. Movement disorder society-sponsored revision of the unified Parkinson's Disease Rating Scale (MDS-UPDRS): scale presentation and clinimetric testing results. *Mov. Disord.* **23**, 2129–2170 (2008).
 39. Folstein, M. F., Folstein, S. E. & McHugh, P. R. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. *J. Psychiatr. Res.* **12**, 189–198 (1975).
 40. Beck, A. T., Ward, C. H., Mendelson, M., Mock, J. & Erbaugh, J. An inventory for measuring depression. *Arch. Gen. Psychiatry* **4**, 561–571 (1961).
 41. Chaudhuri, K. R. et al. The metric properties of a novel non-motor symptoms scale for Parkinson's disease: results from an international pilot study. *Mov. Disord.* **22**, 1901–1911 (2007).
 42. Tossici-Bolt, L. et al. Calibration of gamma camera systems for a multicentre European ¹²³I-FP-CIT SPECT normal database. *Eur. J. Nucl. Med. Mol. Imaging* **38**, 1529–1540 (2011).
 43. Instructions for use hybrid recon. Stockholm, Sweden: Hermes Medical Solutions (2024).
 44. Darcourt, J. et al. EANM procedure guidelines for brain neurotransmission SPECT using (123I)-labelled dopamine transporter ligands, version 2. *Eur. J. Nucl. Med. Mol. Imaging* **37**, 443–450 (2010).
 45. Kaasinen, V., Joutsa, J., Noponen, T., Johansson, J. & Seppänen, M. Effects of aging and gender on striatal and extrastriatal [123I]FP-CIT binding in Parkinson's disease. *Neurobiol. Aging* **36**, 1757–1763 (2015).

Acknowledgements

This study was funded by the Finnish Cultural Foundation, the Finnish Parkinson Foundation, the Päivikki and Sakari Sohlberg Foundation, the Turku University Foundation, and Turku University Hospital (VTR-funds).

Author contributions

E.J. and J.I. contributed equally to this work. V.K. and F.S. conceived and designed the study. E.J., E.M., M.E., S.N., K.M., T.M., T.N., T.I., and R.L. collected the data. E.J., J.I., J.J., T.V., and V.K. contributed to the statistical analyses. E.J. and J.I. wrote the first draft of the manuscript. All authors revised and accepted the final version of the manuscript.

Competing interests

E.J. reports grants from the Finnish Medical Foundation and the Finnish Parkinson Foundation. J.J. reports research grants from the Sakari Sohlberg's Foundation, Finnish Research Council, Finnish Medical Foundation, Sigrid Juselius Foundation, Finnish Foundation for Alcohol Studies, University of Turku and Turku University Hospital; conference travel support from Insightec, AbbVie, and Abbott; consulting for Teva Finland, Summaryx, and Adamant Health; lecturer honoraria from Addiktum, Nordic Infucare, Lundbeck, and Novartis; acting as an advisory board member for Teva Finland; and stock ownership of Neurologic Finland and Suomen Neurolaboratorio. ME has received grants from The Finnish Parkinson Foundation, The Finnish Medical Foundation, Maire Taponen Foundation, The Finnish Brain Foundation, Orion Research Foundation and Turku University Hospital (VTR, internal research funding). KM reports grants from Maire Taponen Foundation, the Hospital District of Helsinki and Uusimaa

and the Finnish Parkinson Foundation. TN reports lecturer honoraria (GE Healthcare) and research grants (GE Healthcare and Turku University Hospital). FS reports consultancies (Abbvie, Axial Biotherapeutics, Orion Pharma, Teva, Adamant Health), honoraria (Abbvie, GE Healthcare, Merck, Teva, Bristol Myers Squibb, Sanofi, Biocodex, Biogen), grants (Emil Aaltonen Foundation, Konung Gustav V:s och Drottning Victorias Stiftelse, Olvi Foundation, Yrjö Jahnsson Foundation, Stockmann Foundation, Sigrid Juselius Foundation, Research Council of Finland, Hospital District of Helsinki and Uusimaa, Renishaw, Orion Pharma, Abbvie), travel expenses (Lundbeck, NordicInfucare), stock (NeuroInnovation Oy, NeuroBiome Oy, Axial Biotherapeutics). V.K. reports advisory boards (Abbvie, Nordic Infucare AB), honoraria (Orion Pharma, Nordic Infucare AB, Abbvie, Eisai, Lundbeck, Teva, Bial), travel expenses (Nordic Infucar AB), grants (the Päivikki and Sakari Sohlberg Foundation, the Finnish Cultural Foundation, the Finnish Parkinson Foundation, the Turku University Foundation, Turku University Hospital (VTR-funds)).

Additional information

Correspondence and requests for materials should be addressed to Elina Jaakkola or Valtteri Kaasinen.

Reprints and permissions information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License, which permits any non-commercial use, sharing, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if you modified the licensed material. You do not have permission under this licence to share adapted material derived from this article or parts of it. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by-nc-nd/4.0/>.

© The Author(s) 2025